Table 3.
The overall sensitivity and specificity performance of serum/plasma or ascitic IL6 to correctly indicate the presence of OC from healthy and benign controls.
| Type | Number of Studies | Sensitivity | Specificity | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Overall | 95% CI | p-Value | τ2 | Overall | 95% CI | p-Value | τ2 | ||
| Serum/plasma IL6 for mixed stages | 7 | 76.7% | 0.646–0.856 | <0.001 | 0.433 | 72% | 0.638–0.790 | <0.001 | 0.165 |
| Ascitic IL6 for mixedstages | 5 | 84% | 0.710–0.919 | <0.001 | 0.492 | 74% | 0.646–0.826 | <0.001 | 0.112 |
| IL6 as one of the combined marker for early stage OC | Gorelik et al., 2005 | 84.1% | Combined with CA124, GCSF, EGF and VEGF | 75.7% | Combined with CA124, GCSF, EGF and VEGF | ||||
| Han et al., 2018 | 84.2% | Combined with CA125, HE4 and ECAD | 95.7% | Combined with CA125, HE4 and ECAD | |||||